Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | PPM1B | O75688 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16840450 | 0.81 | MAPT (0.46) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21061853 | 0.79 | MAPT (0.47) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21061555 | 0.76 | MAPT (0.45) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL25309557 | 0.76 | MAPT (0.45) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL20855705 | 0.76 | MAPT (0.45) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL18255889 | 0.75 | MAPT (0.44) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9388403 | 0.75 | L3MBTL1 (0.49) | MAPTALDH1A1KDM4E | |
| SCHEMBL16841463 | 0.74 | MAPT (0.49) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4251803 | 0.74 | MAPT (0.49) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4251805 | 0.74 | MAPT (0.49) | MAPTALDH1A1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585444-B1 | AZASPIROHEXANONES AS INHIBITORS OF 11-BETA-HSD1 FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| EP-2585444-B1 | AZASPIROHEXANONES AS INHIBITORS OF 11-BETA-HSD1 FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| US-8765744-B2 | Azaspirohexanones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765744-B2 | Azaspirohexanones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765744-B2 | Azaspirohexanones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| EP-2585444-A1 | AZASPIROHEXANONES AS INHIBITORS OF 11-BETA-HSD1 FOR THE TREATMENT OF METABOLIC DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-20120190675-A1 | Azaspirohexanones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190675-A1 | Azaspirohexanones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| US-20120190675-A1 | Azaspirohexanones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
| WO-2011161128-A1 | AZASPIROHEXANONES AS INHIBITORS OF 11-BETA-HSD1 FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011161128-A1 | AZASPIROHEXANONES AS INHIBITORS OF 11-BETA-HSD1 FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190675-A1 | Azaspirohexanones | HSD11B1, HSD3B1, HSD17B1 | MAPT 4827/4885ALDH1A1 131/4885CYP3A4 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.